Latest news
Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila TimesThe Manila Times · Thu, 06 Aug 2026 20:14:27 GMTThe 5 Most Interesting Analyst Questions From Biogen’s Q2 Earnings Call - The Globe and MailThe Globe and Mail · Wed, 05 Aug 2026 05:44:00 GMTReplimune’s Melanoma FDA Decision Pending: This Analyst Sees 40% Upside, ‘High Conviction’ For Approval - TradingViewTradingView · Tue, 04 Aug 2026 10:44:37 GMTReplimune upgraded to Outperform from Market Perform at Leerink - tipranks.comtipranks.com · Tue, 04 Aug 2026 09:48:44 GMTThe Opportunity for Innovation in Desmoid Tumors: A Framework Based on Unmet Need - Leerink PartnersLeerink Partners · Thu, 30 Jul 2026 13:58:57 GMT